A preliminary trial of the effect of recombinant human growth hormone on short‐term linear growth and glucose homeostasis in children with Crohn’s disease

摘要: Summary Background  It is unclear whether recombinant human growth hormone (rhGH) improves linear in children with Crohn’s disease (CD). Aims  To investigate the effects of rhGH on height velocity (HV) and glucose homeostasis over a 6-month period. Design setting  Randomized controlled trial two tertiary children’s hospitals 22 inflammatory bowel amongst whom 21 had CD. Duration from diagnosis number acute relapses requiring either exclusive enteral nutrition or therapeutic dose oral prednisolone were similar treatment control groups. Intervention  Either (0·067 mg/kg per day) as daily subcutaneous injections (rhGH group; n, 11) no rhGH, (Ctrl; for 6 months. Main outcome measure  Percentage change HV after 6 months groups. Auxology, puberty, skeletal age, factors, also assessed. Results  Median increased 4·5 (range, 0·6, 8·9) at baseline to 10·8 (6·1, 15·0) cm/year 6 month (P = 0·003) group, whereas Ctrl it was 3·8 (1·4, 6·7) 3·5 cm/year (2·0, 9·6), respectively (P = 0·58). percentage increase group 140% (16·7, 916·7) compared 17·4% (−42·1%, 97·7%) (P < 0·001). There significant differences activity proinflammatory cytokines both groups bone age chronological In fasting insulin 4·0 11·0) 7·0 mU/l 16·0) (P = 0·02), 3·0 (1·2, 12·7) 3·8 mU/l (2·1, 7·0) (P = 0·72), respectively. Conclusions  Although this pilot shows that can improve short-term CD, clinical efficacy therapy needs be further studied longer-term studies growth, status.